Brief: Hungary Richter CEO says risks in U.S. market currently moderate
13/05/2025 08:41
May 13 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU CEO GABOR ORBAN SAYS: FULL-YEAR GUIDANCE OF AROUND 10% INCREASE IN BOTH REVENUES AND CLEAN EBIT IS MAINTAINED DEAL WITH GRANATA BIO ANNOUNCED TODAY SHOWS MOVE TOWARDS U.S. FERTILITY MARKET RISKS IN THE U.S. MARKET FROM TARIFFS AND PRICING CHANGES ARE MODERATE FOR OUR PRESENT AND NEAR FUTURE Further company coverage: GDRB.BU (Reporting by Anita Komuves) ((KOMUVES.Anita@thomsonreuters.com;))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab